The $100M raise extends the cash runway to 2029, removing near-term financing overhang for a clinical-stage biotech. However, the 14.9% discount pricing signals that the deal was structured to ensure execution, and the heavy allocation to early-stage platforms (50-60% to Nanoprimer) suggests JNJ-1900 (NBTXR3) is not the primary value driver from here. Monitor the final prospectus for full dilution count relative to pre-offering shares outstanding; the adsc used per share count from the offering is modest in absolute terms but should be evaluated against the estimated ~36M basic shares pre-offering.
Price Chart
Executive Summary
Nanobiotix closed its $100M global offering after underwriters fully exercised their option for 33,805 additional ADSs at $38.98 per ADS. The total offering comprised 2,218,467 ordinary shares and 345,099 pre-funded warrants, with net proceeds extending the cash runway into 2029, primarily funding the Nanoprimer platform. The offering is dilutive but provides multi-year visibility for a company with a $1.9B market cap.
Key Financial Metrics
Key Facts
- Total gross proceeds of ~$100M from combined shares and pre-funded warrants
- Underwriters exercised the full over-allotment option for 33,805 additional ADSs at $38.98
- Offering priced at a 14.92% discount to the volume-weighted average price of the ordinary shares on Euronext Paris
- Net proceeds expected to fund operations into 2029
- 50-60% of proceeds allocated to advancing the Nanoprimer and other platforms
- Less than 10% allocated to JNJ-1900 (NBTXR3) development
- Jefferies, TD Cowen, and Stifel acted as global coordinators and joint bookrunners
Financial Impact
$100M gross proceeds raised at $38.98 per ADS, representing a ~14.9% discount to the recent VWAP on Euronext Paris
Risk Factors
- Dilution from 2,218,467 new ordinary shares plus 345,099 pre-funded warrants
- Only <10% of proceeds directed to the lead candidate JNJ-1900 (NBTXR3), implying pipeline shift risk
- 14.9% discount to market price suggests forced execution; may indicate limited demand at market price
- Forward-looking cash runway projections depend on burn rate assumptions that could change with clinical trial expansion
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300358 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+20 | — | — |
Oct 20, 2026 6d ago | 6-K | $25.83 | awaiting T+20 | — | $31.53 (+22.07%) |
Oct 1, 2026 25d ago | 6-K | $25.75 | awaiting T+20 | — | $31.53 (+22.45%) |
Oct 1, 2026 25d ago | Press Release | $25.75 | awaiting T+20 | — | $31.53 (+22.45%) |
Sep 24, 2026 4w ago | 6-K | $33.31 $29.36 | ▲ +11.86% | ▲ +10.38% | $31.53 (+5.34%) |
Sep 24, 2026 4w ago | 6-K | $33.31 $29.36 | ▼ −11.86% | ▼ −10.38% | $31.53 (−5.34%) |
Sep 24, 2026 4w ago | Press Release | $33.31 $29.36 | ▼ −11.86% | ▼ −10.38% | $31.53 (−5.34%) |
Sep 22, 2026 4w ago | Press Release | $35.24 $25.83 | ▼ −26.70% | ▼ −27.39% | $31.53 (−10.53%) |
Sep 14, 2026 6w ago | 6-K | $35.73 $23.40 | ▼ −34.51% | ▼ −36.77% | $31.53 (−11.75%) |
Jul 31, 2026 12w ago | 6-K | $38.89 $40.64 | ▲ +4.50% | ▲ +3.26% | $31.53 (−18.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers